Akebia Therapeutics (NasdaqCM:AKBA) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsErik Ostrowski - CFO and Chief Business OfficerJohn Butler - President, CEO, and DirectorMercedes Carrasco - Senior Director of Investor and Corporate CommunicationsNicholas Grund - Chief Commercial OfficerSteven K. Burke - Senior Vice President, Chief Research and Development OfficerConference Call ParticipantsJulian Harrison - Managing Director and Biotechnology AnalystManagi Nassar - Senior Equity ...

Intellia Therapeutics (NasdaqGM:NTLA) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsEdward Dulac - EVP and CFOJason Fredette - Vice President of Investor Relations and Corporate CommunicationsJohn Leonard - President and CEOLidiya Rizova - Associate, Equity ResearchNone - Company RepresentativeConference Call ParticipantsAlec Stranahan - Senior Analyst, Equity ResearchBrian Cheng - Executive Director and Senior Biotech AnalystJack Allen - Senior Research AnalystJonathan Miller - An ...

Rhythm Pharmaceuticals (NasdaqGM:RYTM) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsCorinne Johnson - Managing DirectorDave Connolly - Head of Investor Relations and Corporate CommunicationsDavid Meeker - Chairman, CEO, and PresidentDerek Archila - Managing Director and Co-Head of Therapeutics ResearchHunter Smith - CFOJennifer Lee - EVP and Head of North AmericaJon Wolleben - Managing DirectorTazeen Ahmad - Managing DirectorYann Mazabraud - EVP and Head of InternationalConference ...

Rhythm Pharmaceuticals (NasdaqGM:RYTM) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsCorinne Johnson - Managing DirectorDave Connolly - Head of Investor Relations and Corporate CommunicationsDavid Meeker - Chairman, CEO, and PresidentDerek Archila - Managing Director and Co-Head of Therapeutics ResearchHunter Smith - CFOJennifer Lee - EVP and Head of North AmericaJon Wolleben - Managing DirectorTazeen Ahmad - Managing DirectorYann Mazabraud - EVP and Head of InternationalConference ...

Zai Lab (NasdaqGM:ZLAB) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsChristine Chiou - SVP of Investor RelationsHaichong Lin - AssociateJonathan Chang - Senior Managing Director of Emerging OncologyJosh Smiley - President and COOLi Watsek - DirectorMichael Yee - Global Head of Biotechnology ResearchRafael Amado - President and Head of Global Research and DevelopmentSamantha Du - Founder, Chairperson, and CEOYajing Chen - CFOConference Call ParticipantsAnupam Rama - Managing Direct ...

Argenx SE (NASDAQ:ARGX) on Thursday announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthenia gravis (oMG).It is an autoimmune disorder where antibodies disrupt nerve-muscle communication, causing variable, fatiguing weakness of eye muscles and eyelids (ptosis) and double vision (diplopia).The study met its primary endpoint, demonstrating statistically significant improvement in patient-reported outcomes.Argenx Says Vyvgart Improves Double Vis ...

Intellia Therapeutics (NasdaqGM:NTLA) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Speaker11Hello, and welcome to Intellia Therapeutics' fourth quarter and full year 2025 conference call. My name is Drew, and I will be your conference operator today. Please be advised that today's call is being recorded. I will now turn the call over to Jason Fredette, Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.Speaker4Thank you, operator. Hello, everyone. Earlier th ...

ImmunityBio Inc. (NASDAQ:IBRX) shares are up during Thursday’s premarket session as the company has completed enrollment in its pivotal randomized trial evaluating Anktiva plus Bacillus Calmette-Guérin (BCG) against BCG alone for treating non-muscle invasive bladder cancer.85% Patients Maintain Complete ResponseThe trial, known as QUILT 2.005, has enrolled 366 patients ahead of schedule, with interim analysis indicating that 85% of those receiving Anktiva plus BCG maintained a complete response at six month ...

VERICEL Q4 2025 RESULTS FEBRUARY 26, 2026 Safe Harbor Vericel cautions you that all statements other than statements of historical fact included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to ...

Transitioned from a vertically integrated COVID-19 vaccine manufacturer to a lean, R&D-focused licensing organization centered on the Matrix-M adjuvant technology. Secured over $800 million in non-dilutive capital over 18 months through strategic milestones and upfront payments from Sanofi and Pfizer. Leveraged the Pfizer agreement to validate Matrix-M's utility across diverse disease areas, with potential for billions in long-term revenue through milestones and royalties. Optimized the operational ...